Sandro Porceddu

Last updated

Sandro Porceddu is a head and neck radiation oncologist at Brisbane's Princess Alexandra Hospital and a Professor with the University of Queensland. [1] He was president of the Clinical Oncologic Society of Australia (COSA) [2] and chair of the Trials Scientific Committee of the Trans Tasman Radiation Oncology Group (TROG). [3]

Contents

Academic career

Porceddu was awarded a doctorate of medicine for his research into improving the integration of radiotherapy in the management of head and neck cancer and received the American Head and Neck Society/ANZ Head and Neck Cancer Society Christopher O'Brien Traveling Scholarship. He is chair of a phase 3 clinical trial group to assess radiation therapy alone versus in combination with carboplatin chemotherapy for the post-operative treatment of head and neck cancers. [4]

Publications

  1. Sandro V Porceddu (2013). "Does fluorodeoxyglucose PET add to the management of the neck following curative radiotherapy in head and neck cancer compared with computed tomography?". Expert Rev Anticancer Ther. 13 (3): 279–84. doi:10.1586/era.13.10. PMID   23477515. S2CID   207214576.
  2. Sandro V Porceddu (2005). "Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer". Head Neck. 27 (3): 175–81. CiteSeerX   10.1.1.469.8139 . doi:10.1002/hed.20130. PMID   15627258. S2CID   21375769.
  3. Sandro V Porceddu (2007). "Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment--"Hypo Trial"". Radiother Oncol. 85 (3): 456–62. doi:10.1016/j.radonc.2007.10.020. PMID   18036689.
  4. Sandro V Porceddu (2008). "Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond". Hematol Oncol Clin North Am. 22 (6): 1221–38, ix–x. doi:10.1016/j.hoc.2008.08.009. PMID   19010270.
  5. S V Porceddu (2008). "Predicting regional control based on pretreatment nodal size in squamous cell carcinoma of the head and neck treated with chemoradiotherapy: a clinician's guide". J Med Imaging Radiat Oncol. 52 (5): 491–6. doi:10.1111/j.1440-1673.2008.02001.x. PMID   19032396. S2CID   38368939.
  6. Sandro V Porceddu (2011). "Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy". Head Neck. 33 (12): 1675–82. doi:10.1002/hed.21655. PMID   22076976. S2CID   3727485.
  7. J Corry (2008). "Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation". J Med Imaging Radiat Oncol. 52 (5): 503–510. doi:10.1111/j.1440-1673.2008.02003.x. PMID   19032398. S2CID   34975490.
  8. D I Pryor (2011). "Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma". Oral Oncol. 1747 (10): 984–7. doi:10.1016/j.oraloncology.2011.07.023. PMID   21852185.
  9. M K Ng (2005). "Parotid-sparing radiotherapy: does it really reduce xerostomia?". Clin Oncol (R Coll Radiol). 17 (8): 610–7. doi:10.1016/j.clon.2005.06.012. PMID   16372486.
  10. Sandro V. Porceddu; Belinda Campbell; Danny Rischin; June Corry; LeAnn Weih; Mario Guerrieri; Marissa Grossi; Lester J. Peters (1 October 2004). "Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma". International Journal of Radiation Oncology, Biology, Physics. 60 (2): 365–373. doi:10.1016/j.ijrobp.2004.03.011. PMID   15380568.
  11. David I Pryor; Benjamin Solomon; Sandro V Porceddu (September 2011). "The emerging era of personalized therapy in squamous cell carcinoma of the head and neck". Asia-Pacific Journal of Clinical Oncology. 7 (3): 236–251. doi:10.1111/j.1743-7563.2011.01420.x. PMID   21884435. S2CID   24908321.

Related Research Articles

<span class="mw-page-title-main">Radiation therapy</span> Therapy using ionizing radiation, usually to treat cancer

Radiation therapy or radiotherapy, often abbreviated RT, RTx, or XRT, is a treatment using ionizing radiation, generally provided as part of cancer therapy to either kill or control the growth of malignant cells. It is normally delivered by a linear particle accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body, and have not spread to other parts. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.

<span class="mw-page-title-main">Cutaneous squamous-cell carcinoma</span> Medical condition

Cutaneous squamous-cell carcinoma (cSCC), or squamous-cell carcinoma of the skin, also known as squamous-cell skin cancer, is, with basal-cell carcinoma and melanoma, one of the three principal types of skin cancer. cSCC typically presents as a hard lump with a scaly top layer, but it may instead form an ulcer. Onset often occurs over a period of months. Cutaneous squamous-cell carcinoma is more likely to spread to distant areas than basal cell cancer. When confined to the outermost layer of the skin, a pre-invasive, or in situ, form of cSCC is known as Bowen's disease.

<span class="mw-page-title-main">Head and neck cancer</span> Cancer arises in the head or neck region

Head and neck cancer develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses, or skin of the face. The most common types of head and neck cancer occur in the lips, mouth, and larynx. Symptoms predominantly include a sore that does not heal or a change in the voice. In those with advanced disease, there may be unusual bleeding, facial pain, numbness or swelling, and visible lumps on the outside of the neck or oral cavity. Given the location of these cancers, trouble breathing may also be present.

<span class="mw-page-title-main">Proton therapy</span> Medical Procedure

In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.

<span class="mw-page-title-main">Merkel-cell carcinoma</span> Rare and highly aggressive skin cancer

Merkel-cell carcinoma (MCC) is a rare and aggressive skin cancer occurring in about three people per million members of the population. It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, and trabecular carcinoma of the skin. Factors involved in the development of MCC include the Merkel cell polyomavirus, a weakened immune system, and exposure to ultraviolet radiation. Merkel-cell carcinoma usually arises on the head, neck, and extremities, as well as in the perianal region and on the eyelid. It is more common in people over sixty years old, Caucasian people, and males. MCC is less common in children.

<span class="mw-page-title-main">Tirapazamine</span> Chemical compound

Tirapazamine (SR-[[4233]]) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.

<span class="mw-page-title-main">Anaplastic thyroid cancer</span> Medical condition

Anaplastic thyroid cancer (ATC), also known as anaplastic thyroid carcinoma, is an aggressive form of thyroid cancer characterized by uncontrolled growth of cells in the thyroid gland. This form of cancer generally carries a very poor prognosis due to its aggressive behavior and resistance to cancer treatments. The cells of anaplastic thyroid cancer are highly abnormal and usually no longer resemble the original thyroid cells and have poor differentiation.

<span class="mw-page-title-main">Mucoepidermoid carcinoma</span> Medical condition

Mucoepidermoid carcinoma (MEC) is the most common type of minor salivary gland malignancy in adults. Mucoepidermoid carcinoma can also be found in other organs, such as bronchi, lacrimal sac, and thyroid gland.

<span class="mw-page-title-main">Fast neutron therapy</span>

Fast neutron therapy utilizes high energy neutrons typically between 50 and 70 MeV to treat cancer. Most fast neutron therapy beams are produced by reactors, cyclotrons (d+Be) and linear accelerators. Neutron therapy is currently available in Germany, Russia, South Africa and the United States. In the United States, one treatment center is operational, in Seattle, Washington. The Seattle center uses a cyclotron which produces a proton beam impinging upon a beryllium target.

<span class="mw-page-title-main">Tomotherapy</span> Type of radiation therapy

Tomotherapy is a type of radiation therapy treatment machine. In tomotherapy a thin radiation beam is modulated as it rotates around the patient, while they are moved through the bore of the machine. The name comes from the use of a strip-shaped beam, so that only one “slice” of the target is exposed at any one time by the radiation. The external appearance of the system and movement of the radiation source and patient can be considered analogous to a CT scanner, which uses lower doses of radiation for imaging. Like a conventional machine used for X-ray external beam radiotherapy, a linear accelerator generates the radiation beam, but the external appearance of the machine, the patient positioning, and treatment delivery is different. Conventional linacs do not work on a slice-by-slice basis but typically have a large area beam which can also be resized and modulated.

The Danish Head and Neck Cancer (DAHANCA) group was established in 1976 as a working group by the Danish Society for Head and Neck Oncology with the primary aim to develop national guidelines for the treatment of head and neck cancer in Denmark.

<span class="mw-page-title-main">Salivary gland tumour</span> Medical condition

Salivary gland tumours, also known as mucous gland adenomas or neoplasms, are tumours that form in the tissues of salivary glands. The salivary glands are classified as major or minor. The major salivary glands consist of the parotid, submandibular, and sublingual glands. The minor salivary glands consist of 800 to 1000 small mucus-secreting glands located throughout the lining of the oral cavity. Patients with these types of tumours may be asymptomatic.

<span class="mw-page-title-main">HPV-positive oropharyngeal cancer</span> Cancer of the throat

Human papillomavirus-positive oropharyngeal cancer, is a cancer of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer.

The term radiogenomics is used in two contexts: either to refer to the study of genetic variation associated with response to radiation or to refer to the correlation between cancer imaging features and gene expression.

Temporal lobe necrosis is a late-stage and serious complication usually occurring in persons who have undergone radiation treatment for nasopharyngeal carcinoma (NPC). It is rather rare and occurs in 4-30% of patients who receive radiation treatment for NPC. Many patients who experience temporal lobe necrosis are asymptomatic. This demonstrates a need for consistent imaging follow up, such as MRI and/or PET/CT, to help with the potential management of it. Those who are symptomatic usually suffer from "vague" symptoms including headaches, dizziness, intracranial pressure, personality changes, seizures, and short-term memory loss. The rarity of this disease has led to difficulty in finding optimal treatments, however, most treatments include one or some of the following: steroids, hyperbaric oxygen, surgery, and decadron.

<span class="mw-page-title-main">FMISO</span> Chemical compound

18F-FMISO or fluoromisonidazole is a radiopharmaceutical used for PET imaging of hypoxia. It consists of a 2-nitroimidazole molecule labelled with the positron-emitter fluorine-18.

<span class="mw-page-title-main">Nancy Y. Lee</span> Radiation oncologist

Nancy Y. Lee is a Taiwanese-born American physician and the vice-chair of the Department of Radiation Oncology in Memorial Sloan Kettering's Department of Medicine.

<span class="mw-page-title-main">Limited-stage small cell lung carcinoma</span> Medical condition

Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a radiation portal. This generally includes cancer to one side of the lung and those might have reached the lymph nodes on the same side of the lung. 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. Common symptoms include but are not limited to persistent cough, chest pain, rust-coloured sputum, shortness of breath, fatigue, weight loss, wheezing, hoarseness and recurrent respiratory tract infections such as pneumonia and bronchitis. Nervous system problems, Cushing syndrome and SIADH can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell lung carcinoma is potentially curable. Standard treatments consist of surgery, platinum-based combination chemotherapy, thoracic irradiation, and prophylactic cranial irradiation. Patient five-year survival rate has significantly increased from 1% with surgery to 26% after the application of combination chemotherapy.

<span class="mw-page-title-main">Nabil F. Saba</span> Atlanta oncologist

Nabil F. Saba is an American oncologist. He is currently Professor and Vice-chair of Hematology and Medical Oncology, and Professor of Otolaryngology at the Winship Cancer Institute at the Emory University School of Medicine in Atlanta, Georgia. He is a specialist in the field of head and neck oncology. Saba has authored more than 200 peer-reviewed articles. He is the inaugural Lynne and Howard Halpern Chair in Head and Neck Cancer Research.

Diffusing Alpha-emitters Radiation Therapy or DaRT is an alpha-particle-based radiation therapy for the treatment of solid tumors.

References

[5] [6] [7] [8]

  1. Bridie Jabour Scans spare PA patients from knife Brisbane Times August 3, 2011
  2. Australia, Cancer Council. "Board and governance - Cancer Council Australia". www.cancer.org.au. Retrieved 26 February 2020.
  3. "TROG Cancer Research". www.trog.com.au. Retrieved 26 February 2020.
  4. Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck ClinicalTrials.gov
  5. "Sandro Porceddu » COSA-IPOS 2012". Archived from the original on 5 September 2013. Retrieved 6 August 2015.
  6. Cathy O'Leary Warning over virus link to cancers The West Australian March 19, 2013
  7. "Archived copy" (PDF). Archived from the original (PDF) on 21 April 2013. Retrieved 6 August 2015.{{cite web}}: CS1 maint: archived copy as title (link)
  8. Associate Professor Sandro Porceddu UQ Researchers